ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in SchizophreniaKrönig H. · Riedel M. · Schwarz M.J. · Strassnig M. · Möller H.-J. · Ackenheil M. · Müller N.
Psychiatric Hospital, Ludwig-Maximilian University Munich, Munich, Germany
Objectives: We have previously reported reduced serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) in schizophrenic patients. A single-nucleotide polymorphism (SNP) of the ICAM-1 gene was described at position 241. The G→A SNP results in a nonsynonymous amino acid exchange of the ICAM-1 protein, and the A allele was shown to be also associated with several immunological disorders like rheumatoid arthritis. Methods: We investigated 70 schizophrenic patients and 128 unrelated healthy control persons regarding the relationship between the serum levels of sICAM-1 and the ICAM-1 G214A polymorphism. Results: We were able to replicate our previous finding of reduced sICAM-1 levels in schizophrenia. Healthy control persons carrying the polymorphic A allele showed markedly lower sICAM-1 serum levels than carriers of the homozygous GG wild type (p < 0.004). In contrast, no significant difference in the sICAM-1 serum levels were seen regarding the G241A genotype distribution in schizophrenic patients. Conclusion: We hypothesize that the biochemical effect of the G241A SNP is masked in schizophrenic patients, indicating a disease-related mechanism leading to reduced levels of sICAM-1 in schizophrenia.
Markus J. Schwarz, MD
Psychiatric Hospital, Ludwig Maximilian University Munich
Nussbaumstrasse 7, DE–80336 Munich (Germany)
Tel. +49 89 5160 2761, Fax +49 89 5160 4741
Received: October 3, 2002
Accepted: March 23, 2004
Number of Print Pages : 6
Number of Figures : 1, Number of Tables : 3, Number of References : 45
Vol. 12, No. 1, Year 2005 (Cover Date: Released March 2005)
Journal Editor: Chrousos, G.P. (Bethesda, Md.)
ISSN: 1021–7401 (print), 1423–0216 (Online)
For additional information: http://www.karger.com/nim